arrow
S

Sung-Bae Kim

university of ulsan
H指数:74
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial

Imlunestrant与或不与Abemaciclib联用治疗晚期乳腺癌:来自Ⅲ期EMBER-3试验的更新疗效结果

2025-12-120
OAAI
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study

帕博利珠单抗联合化疗与化疗对比治疗晚期食管癌:KEYNOTE-590随机III期研究的5年扩展随访

2025-11-180
OAAI
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial

头颈部鳞状细胞癌中Alpelisib对不同PIK3CA突变位点的差异性疗效:来自KCSG HN 15-16 TRIUMPH试验的分析

2025-10-011
PRE
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)

MIRINAE试验(一项比较辅助阿替利珠单抗联合卡培他滨与单用卡培他滨的随机II期试验;KCSG-BR18-21)中,新辅助化疗后残留浸润性三阴性乳腺癌的基因组学和转录组学分析

2025-09-240
PREAI
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

高风险、早期、三阴性乳腺癌患者对新辅助培美曲塞联合化疗反应的分子决定因素:开放标签、多队列1b期KEYNOTE-173研究的探索性分析

2025-03-110
OA
Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence

循环肿瘤DNA纵向动力学在乳腺癌复发患者治疗监测中的应用

2024-08-311
OAAI
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
2024-07-260
OAAI
Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery
2024-07-020
PRE
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial (jun, 10.1038/s41591-024-03060-0, 2024)
2024-06-240
OAAI
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

曲妥珠单抗deruxtecan与曲妥珠单抗emtansine治疗HER2-positive转移性乳腺癌: DESTINY-Breast03试验的长期生存分析

2024-06-026
OAAI
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial
2024-06-012
OAAI
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
2024-04-0228
PRE
Patient-reported outcomes in high-risk HR+ /HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
2024-01-012
PRE
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
2023-12-076
OAAI